---
title: |
  ![](logo.png){width=3in}  
  Phase I Trials - Design Considerations
output:
  html_document:
    df_print: paged
    number_sections: No
    toc: yes
    toc_float: yes
  word_document:
    toc: yes
fontsize: 10pt
editor_options:
  chunk_output_type: console
colorlinks: yes
---

```{r setup, include=FALSE, echo = FALSE,message = FALSE, error = FALSE, warning = FALSE}
knitr::opts_chunk$set(echo = TRUE, fig.width = 10, fig.height = 6)

packages<-c("tidyverse", "kableExtra")

ipak <- function(pkg){
  new.pkg <- pkg[!(pkg %in% installed.packages()[, "Package"])]
  if (length(new.pkg)) 
    install.packages(new.pkg, dependencies = TRUE)
  sapply(pkg, require, character.only = TRUE)
}
ipak(packages)
 
 
setwd(dirname(rstudioapi::getSourceEditorContext()$path))
getwd()
Sys.setlocale("LC_ALL","English")
```


Phase I clinical trials are crucial early steps in the development of new drugs, primarily focusing on assessing the safety, tolerability, and pharmacokinetics (PK) of a compound. These trials are foundational in determining how a new drug behaves in humans, setting the stage for further clinical development.



## Objectives of Phase I Clinical Trials

1. **Safety Assessment**: Phase I trials are designed to identify any adverse effects and determine the safety profile of the compound. This involves monitoring for any immediate toxic effects and other adverse reactions that may occur with increasing doses.

2. **Tolerability**: These trials assess how well subjects can tolerate the new compound, which helps in determining the maximum tolerated dose.

3. **Pharmacokinetics (PK)**: Studying PK involves understanding how the drug is absorbed, distributed, metabolized, and excreted in the body. This information is crucial for setting appropriate dosing regimens for subsequent trials.

## Typical Components of Phase I Trials

- **Single Ascending Dose (SAD) Studies**: These involve administering a single dose of the drug to a small group of subjects, typically starting at a low level and gradually increasing it. Monitoring continues to evaluate safety and PK, with dose escalations contingent on tolerability and absence of severe adverse effects.

- **Multiple Ascending Dose (MAD) Studies**: Following successful SAD studies, MAD studies involve administering repeated doses of the drug to groups of subjects to understand the effects of dose accumulation and to further assess the compound’s safety and tolerability over a more extended period.

- **Special Studies**: Depending on the drug’s profile, additional specialized studies may be conducted, such as food effect studies to see how intake with or without food affects the drug’s absorption and effect, drug-drug interaction studies, and thorough QT/QTc studies to assess potential effects on heart rhythm.


## Design Considerations

- **Dosing Intervals and Levels**: Chosen based on data from SAD studies, these aim to achieve a balance between minimizing risk to the subjects and gathering meaningful pharmacodynamic and pharmacokinetic data.

- **Subject Monitoring**: Intensive monitoring for adverse effects, vital signs, ECG, blood tests, and other relevant parameters is crucial. This monitoring helps in identifying any potential safety issues early in the trial.

- **Statistical and Ethical Considerations**: The design of Phase I trials often involves a careful ethical consideration, particularly regarding subject safety. The use of placebo controls and randomized designs helps to ensure the objectivity and reliability of the trial outcomes.

